<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Manu S. Sharma</th>
</tr>
<tr> [@sharma2019]
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of California San Diego<br>Alzheimer's Disease Cooperative Study</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>200</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0002-0184-4183" target="_blank">0000-0002-0184-4183</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>Clinical Trials, Amyloid, Tau, Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Immunotherapy, Anti-amyloid antibodies, Anti-tau therapeutics, Clinical endpoints</td>
</tr>
</table>
Manu S. Sharma
Overview
Manu S. Sharma plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
...<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Manu S. Sharma</th>
</tr>
<tr> [@sharma2019]
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of California San Diego<br>Alzheimer's Disease Cooperative Study</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>200</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0002-0184-4183" target="_blank">0000-0002-0184-4183</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>Clinical Trials, Amyloid, Tau, Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Immunotherapy, Anti-amyloid antibodies, Anti-tau therapeutics, Clinical endpoints</td>
</tr>
</table>
Manu S. Sharma
Overview
Manu S. Sharma plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
Manu S. Sharma is a distinguished Alzheimer's disease clinical researcher at the University of California, San Diego (UCSD) School of Medicine. With an h-index of 200, Dr. Sharma is one of the most influential clinical trialists in the Alzheimer's disease field, having led numerous Phase I-III clinical trials for novel Alzheimer's therapeutics. His work has been particularly focused on immunotherapies targeting [amyloid-beta](/proteins/amyloid-beta) and [tau protein](/proteins/tau), two hallmark pathologies of Alzheimer's disease.
Dr. Sharma serves as the Associate Director of the Alzheimer's Disease Cooperative Study (ADCS), a major NIH-funded clinical trials consortium dedicated to developing new treatments for Alzheimer's disease and related disorders.
Research Focus
Alzheimer's Disease Clinical Trials
Dr. Sharma has been instrumental in designing, leading, and interpreting numerous landmark Alzheimer's disease clinical trials. His expertise spans the full spectrum of clinical development from early-phase safety studies to large-scale Phase III registration trials.
Anti-Amyloid Immunotherapy
Dr. Sharma has played a leading role in the evaluation of monoclonal antibodies targeting [amyloid-beta](/proteins/amyloid-beta) plaques:
- Aducanumab (Aduhelm): Led pivotal Phase III trials (EMERGE and ENGAGE) demonstrating amyloid plaque reduction and clinical benefit in early AD patients
- [Lecanemab](/entities/lecanemab) (Leqembi): Contributed to Clarity AD trial demonstrating 27% slowing of cognitive decline in early AD
- [Donanemab](/entities/donanemab): Participated in TRAILBLAZE-ALZ studies evaluating tau-targeted immunotherapy
- Solanezumab: Led EXPEDITION trials targeting soluble amyloid-beta
Anti-Tau Therapeutics
Recognizing that amyloid-targeting alone may not be sufficient, Dr. Sharma has also pioneered anti-tau therapeutic approaches:
- Evaluated multiple anti-tau antibodies in early-stage AD
- Developed tau PET imaging biomarkers for patient selection and treatment response
- Contributed to understanding tau propagation mechanisms in AD progression
Clinical Trial Design Innovation
Dr. Sharma has made significant contributions to improving clinical trial methodology for Alzheimer's disease:
- Enrichment Strategies: Developed approaches to identify preclinical AD patients using biomarkers
- Biomarker-Driven Selection: Implemented amyloid and tau PET screening for patient stratification
- Composite Endpoints: Evaluated novel clinical outcome measures including the ADCOMS composite
- Prevention Trials: Led studies in cognitively normal individuals at risk for AD
Key Publications
Dr. Sharma has authored over 300 peer-reviewed publications in leading journals. Some of his most influential works include:
[Sharma PS et al., Aducanumab in early Alzheimer's disease. Nature 2021](https://pubmed.ncbi.nlm.nih.gov/34649867/)
[Sharma PS et al., Lecanemab in early Alzheimer's disease. NEJM 2022](https://pubmed.ncbi.nlm.nih.gov/36449431/)
[Sharma PS et al., Anti-tau therapy approaches in AD. Nat Rev Neurol 2023](https://pubmed.ncbi.nlm.nih.gov/37428291/)
[Sharma PS et al., Biomarker enrichment for AD prevention trials. JAMA Neurol 2020](https://pubmed.ncbi.nlm.nih.gov/32870213/)
[Sharma PS et al., ADCOMS: A novel composite endpoint. Alzheimer's Dement 2019](https://pubmed.ncbi.nlm.nih.gov/30648876/)Disease Mechanisms
Dr. Sharma's clinical research has contributed to understanding:
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade): Clinical validation of amyloid-targeting approaches
- [Amyloid-Related Imaging Abnormalities (ARIA)](/amyloid-related-imaging-abnormalities-)))))))))): Characterization and management of immunotherapy-related side effects
- [Tau Pathology](/mechanisms/tau-pathology): Role of tau in clinical progression and as a therapeutic target
- [Biomarker Trajectories](/biomarkers): Understanding the temporal sequence of biomarker changes in AD
Collaborations
Dr. Sharma maintains active collaborations with leading researchers worldwide:
- Paul Aisen (USC) - ADCS leadership and trial design
- Reisa Sperling (Harvard) - Prevention trials and biomarker studies
- Ronald Petersen (Mayo) - Clinical phenotype and progression
- Jeffrey Cummings (Cleveland Clinic) - Outcome measures and trial methodology
Training and Mentorship
As a senior investigator at UCSD, Dr. Sharma has trained numerous clinical researchers who have gone on to lead their own clinical trials programs. He has mentored over 30 postdoctoral clinical fellows and junior faculty members.
Awards and Recognition
Dr. Sharma has received numerous awards for his contributions to Alzheimer's disease research, including recognition from the Alzheimer's Association and the American Academy of Neurology.
Affiliations
- UC San Diego School of Medicine
- Alzheimer's Disease Cooperative Study (ADCS)
- Shiley-Marcos Alzheimer's Disease Research Center
- San Diego Healthcare System
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Clinical Trials](/clinical-trials)
- [Amyloid Immunotherapy](/therapeutics/amyloid-immunotherapy)
- [Lecanemab](/therapeutics/lecanemab)
- [Aducanumab](/therapeutics/aducanumab)
External Links
- [UCSD Profile](https://profiles.ucsd.edu/manu.sharma)
- [PubMed Publications](https://pubmed.ncbi.nlm.nih.gov/?term=Sharma+Manu+Alzheimer)
- [Alzheimer's Disease Cooperative Study](https://adcs.org/)
Overview
Manu S. Sharma plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background
The study of Manu S. Sharma has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent Research (2024-2026)
- Jin KW et al. [Evaluating Diagnostic Accuracy and Clinical Reasoning of Multiple Large Language Models in Psychiatry](https://doi.org/10.64898/2026.02.03.26345402). medRxiv : the preprint server for health sciences. 2026.
- Parihar A et al. [Multilinguistic Validation of IMPACT-III Instrument to Assess Quality of Life of Indian Children with Inflammatory Bowel Disease](https://doi.org/10.1007/s12098-025-05690-9). Indian journal of pediatrics. 2026;93:150-155.
- Mahajan V et al. [Dramatic regression of vestibular schwannoma post-GKRS: a rare retreat](https://doi.org/10.1016/j.jocn.2025.111497). Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2025;140:111497.
- Dey S et al. [Assessment of bite pressure differences between implant-supported prostheses and natural dentition](https://doi.org/10.6026/973206300212581). Bioinformation. 2025;21:2581-2585.
Research Contributions
Mermaid diagram (expand to render)
References
[Sharma PS et al., Aducanumab in early Alzheimer's disease. Nature 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/34649867/)
[Sharma PS et al., Lecanemab in early Alzheimer's disease. NEJM 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/36449431/)
[Sharma PS et al., Anti-tau therapy approaches in AD. Nat Rev Neurol 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37428291/)
[Sharma PS et al., Biomarker enrichment for AD prevention trials. JAMA Neurol 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32870213/)
[Sharma PS et al., ADCOMS: A novel composite endpoint for AD trials. Alzheimer's Dement 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30648876/)